Medline (NASDAQ:MDLN) Receives $50.54 Consensus PT from Analysts

Medline (NASDAQ:MDLN) has received an average recommendation of “Moderate Buy” from the twenty-nine ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $48.50.

MDLN has been the subject of a number of analyst reports. Citigroup reduced their price objective on shares of Medline from $60.00 to $55.00 and set a “buy” rating for the company in a report on Thursday, May 7th. William Blair reaffirmed an “outperform” rating on shares of Medline in a research report on Thursday, June 4th. BTIG Research reiterated a “buy” rating and set a $55.00 price target on shares of Medline in a research note on Friday, July 31st. Royal Bank Of Canada decreased their price objective on Medline from $53.00 to $46.00 and set an “outperform” rating for the company in a report on Thursday. Finally, Barclays dropped their target price on Medline from $50.00 to $45.00 and set an “overweight” rating on the stock in a report on Monday, June 1st.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported second-quarter revenue of $7.7 billion, up 11.6% year over year, while adjusted EBITDA rose 13.4% to $1.06 billion. Adjusted EPS of $0.50 exceeded the $0.32 analyst consensus. Medline Reports Second Quarter and First Six Months 2026 Results
• Positive Sentiment: Management raised its 2026 organic-sales growth outlook to 9%-10% from 8.5%-9.5%, citing strong demand, new customer wins and existing-customer growth. Operating cash flow and free cash flow also improved substantially in the first half.
• Positive Sentiment: BTIG maintained a Buy rating and $55 price target, while Truist and Stifel retained Buy ratings even after lowering their targets to $47 and $45, respectively. These targets imply analysts still see meaningful upside if Medline executes on its growth plans. BTIG Medline Rating
• Neutral Sentiment: Medline recorded $243 million of net IEEPA tariff-refund benefits in the quarter, partially offset by $89 million in customer repayments. Investors may view this as a temporary benefit rather than a recurring improvement in earnings.
• Negative Sentiment: The company lowered full-year adjusted EBITDA guidance to $3.3-$3.4 billion from $3.5-$3.6 billion. Management cited inflation, higher operating investments, quality-remediation costs, retail-channel weakness and geopolitical pressures.
• Negative Sentiment: Second-quarter net income fell 58.3% to $139 million, and diluted GAAP EPS was only $0.07. A $336 million loss related to the Tracy, California distribution-center fire, along with higher expenses and costs, sharply reduced reported profitability.
• Negative Sentiment: Securities-law firms announced investigations following an FDA warning letter that reportedly identified significant violations. Although the investigations are preliminary, potential regulatory action, litigation costs and operational disruption add to investor uncertainty. Medline Investigation Alert

Insider Activity

In related news, insider Jessi L. Corcoran acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were bought at an average cost of $34.15 per share, for a total transaction of $170,750.00. Following the purchase, the insider owned 5,000 shares in the company, valued at $170,750. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Douglas P. Golwas sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $36.77, for a total transaction of $3,677,000.00. Following the completion of the transaction, the insider owned 23,899 shares in the company, valued at approximately $878,766.23. This trade represents a 80.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.81% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Carlyle Group Inc. bought a new position in Medline in the 4th quarter worth $9,042,728,000. H&F Corporate Investors X Ltd. bought a new position in shares of Medline in the fourth quarter worth about $4,179,591,000. Vanguard Group Inc. purchased a new stake in shares of Medline during the fourth quarter worth about $793,278,000. Morgan Stanley purchased a new stake in shares of Medline during the fourth quarter worth about $636,807,000. Finally, Capital Research Global Investors bought a new stake in Medline during the 4th quarter valued at approximately $620,937,000.

Medline Price Performance

Shares of NASDAQ MDLN opened at $34.51 on Friday. Medline has a twelve month low of $32.81 and a twelve month high of $50.88. The firm has a fifty day simple moving average of $38.24 and a 200 day simple moving average of $41.77. The company has a market capitalization of $45.34 billion and a PE ratio of 107.84. The company has a quick ratio of 2.51, a current ratio of 4.41 and a debt-to-equity ratio of 0.65.

Medline (NASDAQ:MDLN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.18. The business had revenue of $7.68 billion during the quarter. On average, sell-side analysts forecast that Medline will post 1.49 EPS for the current year.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.